Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Catalyst Pharmaceuticals, Inc.

SG&A Expenses: Merck vs. Catalyst Pharmaceuticals

__timestampCatalyst Pharmaceuticals, Inc.Merck & Co., Inc.
Wednesday, January 1, 2014447365411606000000
Thursday, January 1, 2015859701010313000000
Friday, January 1, 201679102609762000000
Sunday, January 1, 201773043999830000000
Monday, January 1, 20181587596110102000000
Tuesday, January 1, 20193688118710615000000
Wednesday, January 1, 2020442337548955000000
Friday, January 1, 2021496280009634000000
Saturday, January 1, 20225818300010042000000
Sunday, January 1, 202313371000010504000000
Loading chart...

In pursuit of knowledge

A Tale of Two Companies: SG&A Expenses in Focus

In the world of pharmaceuticals, operational efficiency is key. Over the past decade, Merck & Co., Inc. and Catalyst Pharmaceuticals, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Merck's SG&A expenses have remained relatively stable, fluctuating around $10 billion annually. In contrast, Catalyst Pharmaceuticals has seen a dramatic increase, with expenses rising nearly 30 times from 2014 to 2023. This surge reflects Catalyst's aggressive expansion and investment in growth. By 2023, Catalyst's SG&A expenses reached approximately 1.3% of Merck's, highlighting the scale difference between the two. This analysis underscores the diverse strategies employed by pharmaceutical giants and emerging players in managing operational costs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025